The view of long noncoding RNAs as nonfunctional “garbage” has been definitely outdated
by the large body of evidence indicating this class of ncRNAs as “golden junk”, especially in …

Simple Summary Long non-coding RNAs (lncRNAs) are generally defined as transcripts
longer than 200 nucleotides and not coding for proteins. This review provides an overview of …

Lymph node metastases are commonly observed in diverse malignancies where they
promote cancer progression and poor outcomes, although the molecular basis is …

EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–
small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of …

Background B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and
anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells' …

Lymphatic metastasis is the leading cause responsible for recurrence and progression in
papillary thyroid cancer (PTC), where dysregulation of long non-coding RNAs (lncRNAs) …

JHDM1D antisense 1 (JHDM1D-AS1), a long non-coding RNA (lncRNA), has been shown to
promote pancreatic cancer growth by inducing an angiogenic response. However, its …

Long noncoding RNAs (lncRNAs) are widely dysregulated in cancer, yet their functional
roles in cancer hallmarks remain unclear. We employ pooled CRISPR deletion to perturb …

Thyroid cancer, the most common endocrine malignancy, has become the most commonly
diagnosed malignant solid tumor. Moreover, some cases have poor prognosis, and the …

Papillary thyroid carcinoma (PTC), accounting for approximately 85% cases of thyroid
cancer, is a common endocrine tumour with a relatively low mortality but an alarmingly high …